Company to hold investor conference call on Monday, July 31, 2023, at 1:30 p.m. PT / 4:30 p.m. ET BRISBANE, Calif., July 30, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc., a clinical-stage biopharmaceutical ...

ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings ANX007 protected key retinal structures important for vision: ...

Vonaprument Has the Potential to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Visual Structures BRISBANE, Calif., ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...

Company Engaging with U.S. and EU Regulatory Authorities to Determine the Optimal Global Pivotal Phase 3 Program for ANX007 BRISBANE, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ...

Potential for Vonaprument to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Structural Measures BRISBANE, Calif., ...

Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation New preclinical ...

-- The unmet need and current treatment landscape for GA -- The mechanism of disease and role of C1q -- Vonaprument, Annexon's neuroprotective C1q inhibitor with the potential to be the first targeted ...

Please provide your email address to receive an email when new articles are posted on . Multimodal imaging and AI are both beneficial for managing patients with geographic atrophy. Cell therapies and ...